| Quarterly Financials | Jun 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 3 | 4 | 5 | 6 | 6 | 6 | 5 |
| Expenses | 3 | 4 | 4 | 5 | 5 | 5 | 5 |
| EBITDA | -0 | -0 | 0 | 1 | 1 | 1 | 1 |
| Operating Profit % | -17 % | -5 % | 6 % | 21 % | 11 % | 16 % | 13 % |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -1 | -1 | 0 | 1 | 0 | 1 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -1 | -1 | 0 | 1 | 0 | 1 | 0 |
| EPS in ₹ | -0.70 | -0.49 | 0.05 | 0.96 | 0.30 | 0.66 | 0.41 |
Aspira Pathlab
Aspira Pathlab
66.96
+2.86
(4.46%)
Key Fundamentals
Market Cap
66.00 Cr
EPS
1.97
PE Ratio
28.70
Dividend Yield
0.00 %
Industry
Healthcare Services 52 Week High
106.78
52 Week Low
45.00
PB Ratio
9.51
Debt to Equity
0.15
Sector
Healthcare Service Provider Actual
Company News
View All News
Five acquirers - Arvind Karsandas Bhanushali, Deepali Arvind Bhanushali, Jay Arvind Bhanushali, Nikunj Velji Mange, and Raj Arvind Bhanushali - along with Shraddha Nikunj Mange have announced an open offer to acquire 26,76,180 equity shares representing 26% of Aspira Pathlab & Diagnostics Limited's total paid-up equity shares. The offer price is set at Rs. 55 per share. The company disclosed this information on September 26, 2025, noting that the open offer follows SEBI takeover regulations.
Aspira Pathlab Approves Q1 FY26 Results and Appoints Woman Independent DirectorAug 12, 2025
Aspira Pathlab & Diagnostics Limited approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. The company reported standalone revenue from operations of Rs 524.80 lakhs and profit after tax of Rs 46.94 lakhs. On a consolidated basis, revenue was Rs 524.80 lakhs with profit after tax of Rs 42.15 lakhs. The board appointed Dr. Alaka Keshav Deshpande as Additional Woman Independent Director for a three-year term from September 27, 2025 to September 26, 2028, subject to shareholder approval. The company also acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP for Rs 13.00 lakhs effective June 30, 2025.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
3,108.10 | #1 26,445.40 | 50.26 | #1 2,554.80 | 11.28 | #1 492 | 24.30 | 43.79 | |
992.05 | 10,295.10 | 67.60 | 699.70 | 23.06 | 144 | 22.54 | 42.12 | |
1,938.20 | 10,103.00 | 65.93 | 1,346.30 | 10.64 | 146 | 18.90 | 38.21 | |
1,243.90 | 6,760.50 | 52.12 | 702.20 | 20.80 | 91 | 81.06 | 51.86 | |
779.10 | 2,643.10 | 31.52 | 742.70 | 16.70 | 78 | 14.53 | 40.44 | |
300.55 | 1,563.20 | 48.21 | 255.90 | 15.11 | 31 | 19.48 | 49.29 | |
1,378.00 | 1,176.60 | 24.27 | 111.60 | 28.72 | 48 | 11.50 | 43.85 | |
305.30 | 986.10 | #1 -6.49 | 1,170.80 | -18.47 | -134 | -35.12 | 49.51 | |
261.00 | 503.60 | 19.21 | 147.80 | #1 134.60 | 19 | #1 444.44 | 44.37 | |
163.30 | 117.60 | 76.21 | 41.80 | 13.28 | 2 | 0.00 | 31.57 |
Growth Rate
Revenue Growth
64.71 %
Net Income Growth
-174.07 %
Cash Flow Change
74.29 %
ROE
-163.10 %
ROCE
-186.18 %
EBITDA Margin (Avg.)
-143.40 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2024 | 2025 |
| Total Assets | 15 | 18 |
| Fixed Assets | 7 | 7 |
| Current Assets | 4 | 5 |
| Capital Work in Progress | 0 | 0 |
| Investments | 0 | 0 |
| Other Assets | 8 | 11 |
| Total Liabilities | 15 | 18 |
| Current Liabilities | 2 | 2 |
| Non Current Liabilities | 3 | 3 |
| Total Equity | 10 | 12 |
| Reserve & Surplus | -5 | -3 |
| Share Capital | 10 | 10 |
Cash Flow
| Cash Flow | 2024 | 2025 |
| Net Cash Flow | 0 | 1 |
| Investing Activities | 0 | 0 |
| Operating Activities | 1 | 2 |
| Financing Activities | -1 | -1 |
Share Holding
| % Holding | Jan 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 36.25 % | 36.25 % | 36.25 % | 36.25 % | 36.25 % | 36.25 % | 36.19 % | 34.55 % | 19.48 % | 19.47 % | 19.37 % | 19.37 % | 18.90 % | 18.90 % | 18.72 % | 18.72 % | 18.55 % | 18.55 % | 18.39 % | 18.39 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 40.41 % | 40.41 % | 40.41 % | 40.33 % | 40.33 % | 41.47 % | 43.33 % | 40.92 % | 52.60 % | 51.49 % | 51.76 % | 51.76 % | 52.24 % | 51.99 % | 55.71 % | 59.15 % | 61.26 % | 60.28 % | 60.46 % | 60.28 % |
| Others | 23.34 % | 23.34 % | 23.34 % | 23.42 % | 23.42 % | 22.28 % | 20.48 % | 24.54 % | 27.91 % | 29.04 % | 28.87 % | 28.87 % | 28.86 % | 29.11 % | 25.57 % | 22.13 % | 20.19 % | 21.18 % | 21.15 % | 21.33 % |
| No of Share Holders | 536 | 535 | 535 | 710 | 852 | 868 | 955 | 1,141 | 1,300 | 1,300 | 1,371 | 1,371 | 1,406 | 1,351 | 1,512 | 1,695 | 1,706 | 1,593 | 1,741 | 1,770 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 16 Nov 2016 |  Change Of Name | NA | 16 Nov 2016 | 0.00 | 0.00 |
| 27 Sept 2024 |  Annual General Meeting | NA | 27 Sept 2024 | 32.42 | 41.39 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 50.14 | 61.75 |
| 07 Feb 2025 | Quarterly Result Announcement | NA | 07 Feb 2025 | 77.00 | 70.07 |
| 16 May 2025 | Quarterly Result Announcement | NA | 16 May 2025 | 63.93 | 56.05 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 69.30 | 65.00 |
| 26 Sept 2025 | Annual General Meeting | NA | 26 Sept 2025 | 63.00 | 61.87 |
Announcements
Announcement under Regulation 30 (LODR)-Open Offer - Updates
6 days ago
6 days agoDraft Letter of Offer6 days ago
6 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025Disclosure Regarding Detailed Public Statement ("DPS") In Relation To The Open Offer To The Public ShareholdersOct 06, 2025
Oct 06, 2025Detailed Public StatementOct 06, 2025
Oct 06, 2025Announcement under Regulation 30 (LODR)-CessationSep 27, 2025
Sep 27, 2025Announcement under Regulation 30 (LODR)-Public Announcement-Open OfferSep 26, 2025
Sep 26, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateSep 26, 2025
Sep 26, 2025Appointment Of Secretarial Auditor Of The CompanySep 26, 2025
Sep 26, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 26, 2025
Sep 26, 2025Public Announcement - Open OfferSep 26, 2025
Sep 26, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2025
Sep 26, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 05, 2025
Sep 05, 2025Letters Dispatched To Non-Email ShareholdersSep 04, 2025
Sep 04, 2025Notice Convening 52Nd Annual General Meeting To Be Held On Friday September 26 2025 At 02.00 P.M Through Video Conferencing Mode.Sep 04, 2025
Sep 04, 2025Reg. 34 (1) Annual Report.Sep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Sep 03, 2025Book Closure Record Date & E-Voting Intimation For The Purpose Of 52Nd Annual General Meeting.Aug 29, 2025
Aug 29, 202552Nd Annual General Meeting To Be Held On Friday September 26 2025 At 02.00 P.M (IST) Through Video Conferencing / Other Audio Visual Means.Aug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 12, 2025
Aug 12, 2025Unaudited Standalone & Consolidated Financial Results For The Quarter Ended June 30 2025Aug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On August 12 2025Aug 12, 2025
Aug 12, 2025Board Meeting Intimation for Approval Of Un-Audited Financial Results (Standalone & Consolidated) For The First Quarter Ended On June 30 2025 And To Transact Other Businesses.Aug 02, 2025
Aug 02, 2025Re-Appointment Of Dr. Pankaj J. Shah (DIN:02836324) As Managing Director & CEO For A Period Of Three (3) Years.
Jul 10, 2025
Jul 10, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 10, 2025
Jul 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Jul 08, 2025Inauguration Of Three (3) New Diagnostics Centers In Gujarat.Jul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 01, 2025
Jul 01, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 10, 2025
Jun 10, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 09, 2025
Jun 09, 2025Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015Jun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015May 28, 2025
May 28, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 17, 2025
May 17, 2025100% Acquisition Of Stake And Strike Off Of Aspira DNA Diagnostics Gujarat LLPMay 16, 2025
May 16, 2025Re-Appointment Of Dr. Pankaj Shah (DIN: 02836324) As Managing Director & CEO Subject To The Members Approval For A Period Of Three (3) YearsMay 16, 2025
May 16, 2025Intimation Of Appointment Of Secretarial Auditor And Internal AuditorMay 16, 2025
May 16, 2025Integrated Filing (Financial)May 16, 2025
May 16, 2025Board Meeting Outcome for Outcome Of The Board Meeting Dated May 16 2025May 16, 2025
May 16, 2025Board Meeting Outcome for Outcome Of The Board Meeting Dated May 16 2025May 16, 2025
May 16, 2025Board Meeting Intimation for Approval Of Audited Standalone & Consolidated Financial Results Of The Company Alongwith The Auditor Report As On March 31 2025May 07, 2025
May 07, 2025Updation In Contact Details Of The Company Registrar And Share Transfer AgentApr 22, 2025
Apr 22, 2025Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2Apr 15, 2025
Apr 15, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 15, 2025
Apr 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Apr 09, 2025Intimation Under Regulation 30 Of The SEBI (LODR) Regulations 2015Apr 08, 2025
Apr 08, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Technical Indicators
RSI(14)
Neutral 54.90
ATR(14)
Less Volatile 3.76
STOCH(9,6)
Neutral 47.17
STOCH RSI(14)
Neutral 45.89
MACD(12,26)
Bullish 0.07
ADX(14)
Weak Trend 11.32
UO(9)
Bearish 47.18
ROC(12)
Uptrend And Accelerating 2.86
WillR(14)
Neutral -45.92
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
